atrial fibrillation
Conditions
Interventions
Experimental group:Rivaroxaban + Ticagrelor
Sponsors
The First Affiliated Hospital of Dalian Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Male or non-pregnant or non-lactating female patients = 18 years of age; 2. Non-valvular atrial fibrillation that requires long-term anticoagulation; 3. Coronary heart disease patients with PCI indications and successful implantation of drug-coated stents; 4. The subjects volunteered to join the study and signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with mechanical or biological valves; 2. Patients with recent thrombolytic therapy; 3. Gastrointestinal bleeding occurred within 1 month during the screening period; 4. Known history of chronic HF prior to screening; 5. Cardiogenic shock within the last 24 hours prior to randomization; 6. Coronary artery bypass graft (CABG) performed or planned for index MI; 7. Massive hemorrhage (hemoglobin at least reduced 2g/dl) or life-threatening bleeding occurred 1 month before screening; 8. Contraindications for anticoagulant or antiplatelet therapy, or an unacceptable risk of bleeding; 9. In the past half a year, there were stroke, TIA, cerebral hemorrhage and so on; 10. Anemia (hemoglobin 3.0 mg/dL or increased ammonia levels, if performed), or history of cirrhosis with evidence of portal hypertension such as esophageal varices; 15. There is a need for patients to continue to receive non-steroidal anti-inflammatory drugs (NSAIDs). 16. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin) within the past 3 years with a life expectancy of less than 1 year. 17. Those who were participating in another clinical trial had not yet reached the end of the study or were planning to participate in another clinical trial within six months of taking the drug.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| clinical bleeding events;compound end point of major CV adverse events (MI, stroke or CV death); | — |
Countries
China
Contacts
Public ContactZhang Bo
The First Affiliated Hospital of Dalian Medical University
Outcome results
None listed